A landmark $16M clinical trial led by Sylvester Comprehensive Cancer Center will assess AI's impact on radiologist performance in mammography screening.
Key Details
- 1PRISM is the first major randomized U.S. trial to study AI in breast cancer screening.
- 2Supported by a $16 million award from PCORI, the study spans hundreds of thousands of mammograms across six states.
- 3Seven academic medical centers, including UCLA and University of Miami, are participating.
- 4The trial uses Transpara by ScreenPoint Medical as the AI tool, integrated via Aidoc aiOS.
- 5Radiologists will remain in control of interpretations, with randomized assignment to AI-assisted or radiologist-only reads.
- 6Outcomes include cancer detection, recall rates, and perceptions of AI from both patients and clinicians.
Why It Matters
This large, multicenter trial could establish high-level evidence on the true value of AI assistance in real-world breast imaging, directly influencing clinical implementation, policy, and practice. Its patient-centered design and rigorous methodology will help clarify how—and for whom—AI can best improve breast cancer screening results.
Source
EurekAlert
Related News
•EurekAlert
Deep Learning Model Predicts Language Outcomes After Cochlear Implants Using MRI
AI model using deep transfer learning accurately predicts spoken language outcomes in deaf children after cochlear implantation based on pre-implantation brain MRI scans.
•EurekAlert
AI-Driven CT Tool Predicts Cancer Spread in Oropharyngeal Tumors
Researchers have created an AI tool that uses CT imaging to predict the spread risk of oropharyngeal cancer, offering improved treatment stratification.
•EurekAlert
AI Model PRTS Predicts Spatial Transcriptomics From H&E Histology Images
Researchers developed PRTS, a deep learning model that infers single-cell spatial transcriptomics from standard H&E-stained tissue images.